Although single isoform specific Aurora inhibitors were developed, pan-Aurora inhibitors and even those with an additional anti-cancer pharmacology, such as fms-like tyrosine kinase 3 (FLT3) inhibition were also pursued (Bavetsias and Linardopoulos, 2015; Pollard and Mortimore, 2009). The gene discussed is FLT3; the disease is cancer.